Sogen Data · Datasets · 数据专题
子宫内膜癌复发轴数据集锦
单细胞 · bulk 转录组
本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。
人源bulk 转录组
Human · Bulk RNA-seq
-
01 GSE216872 本研究纳入61名子宫内膜癌患者(1991-2010年),按是否复发分为7例复发组(病例)和54例非复发组(对照),提取总RNA进行RNA-Seq测序,比较两组间基因表达差异。
设计本研究纳入61名子宫内膜癌患者(1991-2010年),按是否复发分为7例复发组(病例)和54例非复发组(对照),提取总RNA进行RNA-Seq测序,比较两组间基因表达差异。
摘要Endometrial cancer (EC) incidence and mortality continues to rise. Molecular profiling of EC promises improvement of risk assessment and treatment selection. Though, we still lack robust and accurate models to predict those at risk of failing treatment. The objective of this pilot study is to create models with clinical and genomic data that will discriminate patients with EC at risk of disease recurrence. We performed a pilot, retrospective, case-control study evaluating patients with EC, endometrioid type: 7 with recurrence of disease (cases), and 54 without (controls). RNA was extracted from frozen specimens and sequenced (RNAseq). Genomic features from RNAseq included transcriptome expression, genomic, and structural variation. Feature selection for variable reduction was performed with univariate ANOVA with cross-validation. Selected variables, informative for EC recurrence, were introduced in multivariate lasso regression models. Validation of models was performed in machine learning platforms (ML) and independent datasets (TCGA). The best performing prediction models (out of >170) contained the same lncRNA features (AUC of 0.9, and 95% CI: 0.75, 1.0). Models were validated with excellent performance in ML platforms and good performance in an independent dataset. Prediction models of EC recurrence containing lncRNA features have better performance than models with clinical data alone
-
02 GSE178671 针对低风险和中等风险子宫内膜癌患者开展病例对照研究,复发病例与非复发病例按年龄和FIGO分期以2:1比例匹配,共纳入17例复发和34例非复发患者,实际分析49例。采用nCounter® PanCancer Pathways Panel检测770个基因的表达,比较复发与非复发组的基因表达差异。
设计针对低风险和中等风险子宫内膜癌患者开展病例对照研究,复发病例与非复发病例按年龄和FIGO分期以2:1比例匹配,共纳入17例复发和34例非复发患者,实际分析49例。采用nCounter® PanCancer Pathways Panel检测770个基因的表达,比较复发与非复发组的基因表达差异。
摘要The molecular profile of endometrial cancer has become an important tool in determining patient prognosis and their optimal adjuvant treatment. In addition to The Cancer Genome Atlas (TCGA), simpler tools have been developed, such as the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE). We attempted to determine a genetic signature to build a recurrence risk score in patients diagnosed with low- and intermediate-risk endometrial cancer. A case-control study was conducted. The eligible patients were women diagnosed with recurrence low- and intermediate-risk endometrial cancer between January 2009 and December 2014 at a single institution; the recurrence patients were matched to two nonrecurrence patients with the same diagnosis by age and surgical staging. Following RNA isolation of 51 cases, 17 recurrence and 34 nonrecurrence patients, the expression profile was determined using the nCounter® PanCancer Pathways Panel, which contains 770 genes. The expression profile was successfully characterized in 49/51 (96.1%) cases. We identified 12 genes differentially expressed between the recurrence and nonrecurrence groups. The ROC curve for each gene was generated, and all had AUCs higher than 0.7. After backward stepwise logistic regression, four genes were highlighted: FN1, DUSP4, LEF1, and SMAD9. The recurrence risk score was calculated, leading to a ROC curve of the 4-gene model with an AUC of 0.93, sensitivity of 100%, and specificity of 72.7%. We identified a four-gene signature that is associated the risk of recurrence in patients with low- and intermediate-risk endometrial cancer. This finding suggests a new prognostic factor in this poorly explored group of patients with endometrial cancer.
鼠源单细胞
Mouse · Single-cell
-
01 GSE292814 对子宫内膜癌复发小鼠模型的原发肿瘤与复发肿瘤进行单细胞核RNA测序和常规RNA测序,比较两种肿瘤类型的转录特征差异。
设计对子宫内膜癌复发小鼠模型的原发肿瘤与复发肿瘤进行单细胞核RNA测序和常规RNA测序,比较两种肿瘤类型的转录特征差异。
摘要We developed the first clinically relevant, immunocompetent SEC mouse model incorporating PIK3CA mutation, TP53 loss, and MYC overexpression. Through comprehensive analysis integrating mouse models, human cell lines, xenografts, and clinical samples, we investigated mechanisms of PIK3CA-targeted therapy resistance. Single-cell transcriptional profiling identified FGFR1/2 association with intrinsic resistance and FGFR3 with acquired resistance. Dual inhibition of FGFR and PI3Ka achieved enhanced tumor suppression. Additionally, we discovered that FGFR signaling promotes immune evasion by downregulating MHC-I/HLA-mediated antigen processing and presentation. Importantly, FGFR inhibition not only reversed immune suppression by restoring antigen presentation but also demonstrated a synergistic effect with anti-PD-1 therapy, enhancing immunotherapy response and anti-tumor immune memory. Our findings reveal FGFR's dual role in therapy resistance and immune evasion, supporting FGFR inhibition as a promising strategy to enhance treatment outcome in SEC patients.
鼠源bulk 转录组
Mouse · Bulk RNA-seq
-
01 GSE311373 将携带 PIK3CA 突变、TP53 丢失和 C-MYC 过表达的 SEC 小鼠模型分为 KrasG12D; PTEN-/-_1、PTEN-/-_2、APM、Rec1、Rec9 等基因型组,撤除多西环素后监测数月,收集原发与复发肿瘤组织进行 RNA-seq 分析,比较不同基因型在肿瘤复发前后的转录组差异。
设计将携带 PIK3CA 突变、TP53 丢失和 C-MYC 过表达的 SEC 小鼠模型分为 KrasG12D; PTEN-/-_1、PTEN-/-_2、APM、Rec1、Rec9 等基因型组,撤除多西环素后监测数月,收集原发与复发肿瘤组织进行 RNA-seq 分析,比较不同基因型在肿瘤复发前后的转录组差异。
摘要We developed the first clinically relevant, immunocompetent SEC mouse model incorporating PIK3CA mutation, TP53 loss, and MYC overexpression. Through comprehensive analysis integrating mouse models, human cell lines, xenografts, and clinical samples, we investigated mechanisms of PIK3CA-targeted therapy resistance. Single-cell transcriptional profiling identified FGFR1/2 association with intrinsic resistance and FGFR3 with acquired resistance. Dual inhibition of FGFR and PI3Ka achieved enhanced tumor suppression. Additionally, we discovered that FGFR signaling promotes immune evasion by downregulating MHC-I/HLA-mediated antigen processing and presentation. Importantly, FGFR inhibition not only reversed immune suppression by restoring antigen presentation but also demonstrated a synergistic effect with anti-PD-1 therapy, enhancing immunotherapy response and anti-tumor immune memory. Our findings reveal FGFR's dual role in therapy resistance and immune evasion, supporting FGFR inhibition as a promising strategy to enhance treatment outcome in SEC patients.

课题合作 · 扫码加微信
bioinformaticsboy